Merck Announces First Quarter 2011 Financial Results

Merck MRK today announced financial results for the first quarter of 2011. Double-Digit EPS Growth in First Quarter 2011: Non-GAAP EPS of $0.92; GAAP EPS of $0.34 Double-Digit Global Growth for JANUVIA, JANUMET, SINGULAIR, REMICADE, NASONEX and ISENTRESS; Key Product Launches Underway Pharmaceutical, Animal Health and Consumer Care Divisions All Contributed Solid Revenue Growth Company Updates Full-Year 2011 EPS Targets: Non-GAAP EPS Range of $3.66 to $3.76; GAAP EPS Range of $2.04 to $2.39